ANGPTL3: A promising therapeutic direction for cardiovascular disease
Despite major advances in the treatment of cardiovascular disease, or CVD, with statins, antihypertensive and antithrombotic drugs, a residual number of patients with CVD remain untreated. These patients have a genetic disorder or extremely high levels of triglycerides (hypertriglyceridemia) that render them unresponsive to current therapies. To find new therapies, researchers are targeting circulating lipids and lipoproteins. A sedentary lifestyle and a diet high in sugar, fat and processed carbohydrates increase a person’s risk of developing CVD.
with a flavored 15% fructose solution and then treated with fish oil
supplements to demonstrate the role of diet on ANGPTL3 protein levels.
Two main sugars in the human diet are glucose and fructose. Glucose, the major component of dietary carbohydrates, is a product of starch. Fructose is found mainly in soft drinks and other beverages, desserts and candies. Although similar in calories, glucose and fructose are metabolized differently. Glucose is absorbed rapidly by almost all cells in the body, and its levels remain balanced through insulin release. Fructose is metabolized mainly by the liver, and its levels are not regulated by insulin; increased fructose consumption increases circulating triglycerides, low-density lipoprotein cholesterol, and fat around organs and blood vessels. In the process of de novo lipogenesis, fructose in the liver metabolizes to lipids.
The liver expresses and secretes angiopoietinlike 3, or ANGPTL3, which plays a role in lipid clearance; therefore, scientists see this protein as a promising therapeutic target for developing lipid-lowering drugs that target formation of triglycerides. In a recent paper in the Journal of Lipid Research, Peter Havel and colleagues wrote that consumption of dietary fructose increases circulating levels of ANGPTL3 in rhesus macaques by 30% to 40%. Increased ANGPTL3 correlated with increased levels of plasma triglycerides.
In collaboration with Arrowhead Pharmaceuticals, the authors found that inhibiting hepatic ANGPTL3 expression using RNA interference technology resulted in reduced circulating ANGPTL3 and triglycerides in rhesus macaques. Supplementing the macaques’ diet with fish oil led to decreased levels of ANGPTL3.
“These are the first studies to demonstrate the effect of diet (fructose and omega-3 fatty acids in fish oil) on ANGPTL3,” Havel said, “and suggest that ANGPTL3 is a promising target for management of hypertriglyceridemia.”
The role of dietary sugars in metabolism is a focus of Havel’s lab at the University of California, and the researchers have developed the rhesus macaque model of metabolic syndrome “in which consuming sugar-sweetened beverages accelerates the development of insulin resistance and dysregulation of lipid metabolism,” he said.
For patients with CVD who can’t benefit from current treatments, this research opens exciting possibilities for new therapies. “Suppression of ANGPTL3 production may be an important mechanism,” Havel said. “Fish oil supplements, when consumed in adequate amounts, lower plasma triglycerides and reduces CVD risk.”
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
The relationship between two proteins, one essential to mitochondrial fission and the other found in Alzheimer’s tissue, might hold the key to how disease alters the fission–fusion balance.
Preliminary evidence seems to suggest that someone who’s vaccinated is less likely transmit the virus, but the proof is not yet ironclad.
An enzyme previously linked to lymphoma development may have more functions than previously thought.
Neurochemist Xianlin Han has been an associate editor for the Journal of Lipid Research since 2019.